4.7 Article

Cytokine production capacity in depression and anxiety

Journal

TRANSLATIONAL PSYCHIATRY
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/tp.2016.92

Keywords

-

Categories

Funding

  1. Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw) [10-000-1002]
  2. VU University Medical Center
  3. GGZ inGeest
  4. Arkin
  5. Leiden University Medical Center
  6. GGZ Rivierduinen
  7. University Medical Center Groningen
  8. Lentis
  9. GGZ Friesland
  10. GGZ Drenthe
  11. IQ Healthcare
  12. Netherlands Institute for Health Services Research (NIVEL)
  13. Netherlands Institute of Mental Health and Addiction (Trimbos)
  14. EMGO Institute for Health and Care Research
  15. BWP through a VICI grant (NWO) [91811602]
  16. Hersenstichting Nederland [2011(1)-134]

Ask authors/readers for more resources

Recent studies have suggested that immune function may be dysregulated in persons with depressive and anxiety disorders. Few studies examined the expression of cytokines in response to ex vivo stimulation of blood by lipopolysaccharide (LPS) to study the innate production capacity of cytokines in depression and anxiety. To investigate this, baseline data from the Netherlands Study of Depression and Anxiety (NESDA) were used, including persons (18-65 years; 66% women) with current (that is, past month; N = 591) or remitted (N = 354) DSM-IV depressive or anxiety disorders and healthy controls (N = 297). Depressive and anxiety symptoms were measured by means of the Inventory of Depressive Symptomatology (IDS) and the Beck Anxiety Inventory (BAI). Using Multi-Analyte Profiling technology, plasma levels of 13 cytokines were assayed after whole blood stimulation by addition of LPS. Basal plasma levels of C-reactive protein, interleukin-6 and tumor necrosis factor-alpha were also available. A basal and a LPS summary index were created. Results show that LPS-stimulated inflammation was associated with increased odds of current depressive/anxiety disorders (odds ratio (OR) = 1.28, P = 0.009), as was the case for basal inflammation (OR = 1.28, P = 0.001). These associations were no longer significant after adjustment for lifestyle and health (OR = 1.13, P = 0.21; OR = 1.07, P = 0.45, respectively). After adjustment for lifestyle and health, interleukin-8 was associated with both remitted (OR = 1.25, P = 0.02) and current (OR = 1.28, P = 0.005) disorders. In addition, LPS-stimulated inflammation was associated with more severe depressive (beta = 0.129, P<0.001) and anxiety (beta = 0.165, P<0.001) symptoms, as was basal inflammation. Unlike basal inflammation, LPS-stimulated inflammation was still associated with (anxiety) symptom severity after adjustment for lifestyle and health (IDS: interleukin (IL)-8, MCP-1, MMP2; BAI: LPS index, IL-6, IL-8, IL-10, IL-18, MCP-1, MMP2, TNF-beta). To conclude, lifestyle and health factors may partly explain higher levels of basal, as well as LPS-stimulated inflammation in persons with depressive and anxiety disorders. However, production capacity of several cytokines was positively associated with severity of depressive and in particular anxiety symptoms, even while taking lifestyle and health factors into account. Elevated IL-8 production capacity in both previously and currently depressed and anxious persons might indicate a genetic vulnerability for these disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available